Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
P/E ratio for Biogen Inc. (BIIB)
P/E ratio as of 2023: 32.25
According to Biogen Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 32.25. At the end of 2022 the company had a P/E ratio of 13.21.
P/E ratio history for Biogen Inc. from 1985 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 32.25 |
| 2022 | 13.21 |
| 2021 | 22.99 |
| 2020 | 9.85 |
| 2019 | 9.43 |
| 2018 | 13.92 |
| 2017 | 26.67 |
| 2016 | 16.73 |
| 2015 | 19.93 |
| 2014 | 27.34 |
| 2013 | 35.57 |
| 2012 | 25.24 |
| 2011 | 21.61 |
| 2010 | 16.83 |
| 2009 | 15.85 |
| 2008 | 17.78 |
| 2007 | 28.17 |
| 2006 | 76.57 |
| 2005 | 94.55 |
| 2004 | 889.50 |
| 2003 | -7.46 |
| 2002 | 25.50 |
| 2001 | 37.50 |
| 2000 | 84.53 |
| 1999 | 66.82 |
| 1998 | 25.00 |
| 1997 | 28.46 |
| 1996 | 42.91 |
| 1995 | 125.56 |
| 1994 | -14.22 |
| 1993 | 22.12 |
| 1992 | 31.25 |
| 1991 | 203.13 |
| 1990 | 219.16 |
| 1989 | 117.19 |
| 1988 | -937.50 |
| 1987 | -72.12 |
| 1986 | -52.08 |
| 1985 | -72.12 |